Antibody targeting of LOXL2, which is the other member of the lysyl oxidase family that is highly expressed in NSCLC, have yielded disappointing results in clinical trials in pancreatic and metastatic colorectal cancer (202, 203) but, like LOX inhibitors, may yet prove effective in NSCLC treatment. This evidence concerns the gene LOX and metastatic colorectal cancer.